This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Stealth BioTherapeutics Management
Management criteria checks 1/4
Key information
Reenie McCarthy
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | 4.1yrs |
CEO ownership | 0.2% |
Management average tenure | no data |
Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Stealth Biotherapeutics chief financial officer Robert Weiskopf leaves company
Sep 30Stealth BioTherapeutics shares pop ~20% premarket after co agrees to go private
Aug 01Stealth BioTherapeutics: A Net-Net Biopharma Going Private
Jul 26Stealth BioTherapeutics receives Nasdaq non-compliance receipt
Jul 11Stealth Biotherapeutics shares soar on EMA orphan drug status for elamipretide
Jun 01Stealth BioTherapeutics skyrockets on data for elamipretide studies
May 06FDA accepts Stealth Bio's Pre-NDA meeting request for elamipretide
Jan 06Reflecting on Stealth BioTherapeutics' (NASDAQ:MITO) Share Price Returns Over The Last Year
Dec 31Stealth Bio launches $3.2M registered direct offering
Nov 20CEO
Reenie McCarthy (57 yo)
4.1yrs
Tenure
Ms. Irene P. McCarthy, also known as Reenie, J.D., has been President, Chief Executive Officer and Secretory of Stealth BioTherapeutics Corp (formerly known as Stealth BioTherapeutics Inc.) since October 2...
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 4.4yrs | no data | 0.19% $ 45.9k | |
Independent Non-Employee Director | 4.4yrs | no data | 0% $ 0 | |
Independent Non-Employee Director | 4.4yrs | no data | 0% $ 0 | |
Independent Director | 3.3yrs | no data | 0% $ 0 | |
Chairman of the Board | 4.4yrs | no data | 0% $ 0 | |
Director | 1.9yrs | no data | 0% $ 0 | |
Non-Employee Director | 5.3yrs | no data | 0.11% $ 25.9k |
4.4yrs
Average Tenure
72yo
Average Age
Experienced Board: MITO's board of directors are considered experienced (4.4 years average tenure).